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The use of human urine as a diagnostic tool hasmany advantages, such as ease of sample acquisition and noninvasiveness. However,
the discovery of novel biomarkers, as well as biomarker patterns, in urine is hindered mainly by a lack of comparable datasets. To
fill this gap, we assembled a new urinary fingerprint database. Here, we report the establishment of a human urinary proteomic
fingerprint database using urine from 200 individuals analysed by SELDI-TOF (surface enhanced laser desorption ionisation-time
of flight) mass spectrometry (MS) on several chip surfaces (SEND, HP50, NP20, Q10, CM10, and IMAC30).The database currently
lists 2490 unique peaks/ion species from 1172 nonredundant SELDI analyses in the mass range of 1500 to 150000. All unprocessed
mass spectrometric scans are available as “.xml” data files. Additionally, 1384 peaks were included from external studies using CE
(capillary electrophoresis)-MS, MALDI (matrix assisted laser desorption/ionisation), and CE-MALDI hybrids. We propose to use
this platform as a global resource to share and exchange primary data derived fromMS analyses in urinary research.
1. Introduction
Screening of human tissues and biofluids for disease bio-
markers is an important task in healthcare and disease
prevention but is often hindered by the complexity of the
system studied, for example, plasma. A substantially less
complex system such as urine, which contains approximately
3000 proteins [1, 2], would be a preferred medium to screen
for protein or peptide biomarkers as sampling is both simple
and noninvasive, and unrestricted quantities are obtainable.
Urine is relatively stable in terms of protein/peptide composi-
tion and fragmentation state comparedwith other body fluids
such as serum, where proteolytic degradation by endogenous
proteases has been shown to occur during or after sample
collection [3]. Several investigations have been published
describing the urinary peptidome and proteome [4, 5],
including biomarker discoveries for several disease processes
[6–10]. These studies have used methodologies ranging from
traditional 2D gel electrophoresis alone [11] or coupled with
mass spectrometry (2-DE-MS) [12], immunohistochemistry
[13], liquid chromatography mass spectrometry (LC-MS)
[14], and surface enhanced laser desorption ionisation-time
of flight mass spectrometry (SELDI-TOF-MS) [15–17].
In complex disease processes, the identification of bio-
markers is key to developing novel therapeutic target mol-
ecules. Identification of the most robust urinary biomarkers
will be enhanced by collating and correlating data from other
published and current studies. Currently there are a number
of urinary databases available. The majority consists of lists
of identified proteins derived from tryptic digests analysed by
LC-MS/MS, such as MAPU [18] and Sys-BodyFluid [19] and
does not cover naturally occurring mass-centric molecular
entities. More recently, a urinary database, combining chro-
matographic reverse-phase retention times and m/z values,
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has been established [20]. The Mosaiques database [21, 22]
consists of naturally occurring protein and peptide patterns
detected by capillary electrophoresisMS (CE-MS) frommore
than 3600 individuals, coveringmainly anm/z range of 800 to
3000.However, databases that give access to unprocessed data
files are not available but would be the most useful resource
with which to compare and validate novel datasets.
It is also prudent, especially in urinary proteome research,
to remember that any peak in any MS scan profile might
be derived from the same molecule (differing only in either
its fragmentation or posttranslational modifications). This
differentiation might be lost in an MS/MS screen, where
proteolytic processing of the samples might alter the origi-
nal protein/peptide signatures and intensities. Additionally,
such fragmentation steps are also time consuming and
decrease the sensitivity of the analysis. Other technologies
such as ESI (electrospray ionization) methods require off-
line fractionation and sample clean-up steps, which can be
avoided using LC-MS as a platform. However, the limitation
of the inline LC step, usually employing a reverse-phase
resin as a solid matrix, narrows the general usability of
this method. Alternatives which allow a suitable range of
inline fractionation steps using various resins is SELDI, and
a novel emerging alternative termed material-enhanced laser
desorption/ionization (MELDI) [23, 24], where biomolecules
are absorbed onto a solid phase resin and directly used for
mass analysis using MALDI.
We chose the high-throughput SELDI-TOF-MS technol-
ogy as our platform for biomarker pattern screening. The
main advantages of the SELDI technology are its ease of use
including little or no sample preparation, high reproducibil-
ity, high volume throughput in a minimum of time, with
proven methodology over time for the numerous diseases
studied, whereas MELDI might require further development
before it can be generally applied.Themain limitations of the
SELDI technology lie with the instrumentation where poor
resolution on older instruments led to difficult reproducibil-
ity and sometimes questionable results. However, we have
chosen amoremodern technology (see Section 2). A number
of reviews list the issues and compares the various MS-based
methods in urinary research [25–27].
Utilizing data from both our own and published stud-
ies, we have established the urinary proteome fingerprint
database UPdb, which will be publically available as a repos-
itory for SELDI-MS data and as a reference for scientists to
probe the urinary proteome for proteins implicated in disease
processes.
2. Materials and Methods
2.1. Urine Samples. Urine samples were obtained from 86
cancer patients, 93 noncancer controls, and 21 patients with a
previous history of cancer but were diagnosed as cancer-free
6 to 18months after resectional surgery. Summary participant
demographics are shown in Table 1, and full details are
provided as part of the database. The cancer sample urines
were collected just prior to surgery. One-third of the cancer
patients were diagnosed with pancreatic tumours, approx-
imately one-third had oesophageal cancer, approximately
one-sixth had malignancies of the oesophagogastric junction
(OGJ), and approximately one-sixth suffered from gastric
cancer. All procedures were approved by the local research
ethics committee. Written informed consent was obtained.
The study conformed to the standards set by the Declaration
of Helsinki. All urine samples were stored at −40∘C.
2.2. SELDI-TOF MS. 0.1mL human urine was applied di-
rectly to preconditioned SELDI ProteinChip arrays (Bio-
Rad Laboratories Inc.) (NP20, H50, SEND, Q10, CM10
and IMAC30), as recommended by the manufacturer, in a
ProteinChip bioprocessor and incubated with 0.1mL bind-
ing buffer where appropriate. The chip-spots were washed
with 0.2mL binding buffer three times and air-dried, fol-
lowed by application of emitter matrix (alpha-cyano-4-
hydroxycinnamic acid (CHCA) or sinapinic acid (SPA)).The
arrays were read twice, one at low laser settings (focused on
100–50,000Dam/z) and one at high laser settings (focused on
1000–200,000Da m/z), on a ProteinChip Enterprise System
PCS4000 (BioRad Laboratories Inc.), SELDI-TOF instru-
ment, and spectral data collected over an average of 588 shots
per spot using ProteinChip Data Manager software. Files
were exported in “.xml” format. All spectra were processed
using the expression differencemapping (EDM)wizard in the
ProteinChip Data Manager software (BioRad Laboratories
Inc.) with a signal-to-noise-ratio cutoff of 5%, 3% valley
depth, and a cluster mass window of 0.2%m/z.
3. Results and Discussion
SELDI-MS analysis of human urine samples has been re-
ported to show little intra- and interchip variation, as well
as low intraindividual day-to-day variation [19] and has been
established as a key emerging technology to discover new
biomarkers for a variety of diseases. We chose to establish a
repository for urinary SELDI data to bemade available for the
scientific community in order to enable an open exchange of
research findings and data sharing.
We analysed the 200 urine specimens using the SELDI-
MS platform on various chip types, ranging from small sized
screens of 21 samples on NP20 and HP50 surfaces, medium-
sized screens of 63 samples on SEND and Q10 surfaces, and
full screens of all 200 samples on CM10 and IMAC30 chip-
types (Table 2). The selection of the appropriate chip-surface
for a screening purpose depends on many factors, such
as peak intensities, distribution, and the number of clearly
identifiable ion species (Figure 1). However, under certain
conditions a nonoptimal chip type might resolve potential
biomarkers and biomarker patterns better than another one.
We chose to evaluate all commonly used chip surfaces.
Both CM10 and IMAC30 (Cu2+) gave the best results in
terms of signal intensities, peak resolution, and the number
of observable peaks. A similar finding has been reported
previously using a single urine specimen [16]. Figure 1 shows
the SELDI-MS scans of two samples on the six surfaces tested.
We also observed that urines from different individuals
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Figure 1: Example of SELDI mass spectra of human urine using various chip surfaces. 0.1mL urine from a healthy control sample (a) and
from a cancer patient (b) was applied to the chip surfaces, as recommended by the manufacturer and analysed by SELDI-TOF. The spectra
are plotted asm/z (6000 to 13500) against intensity.
Table 1: General overview of the study cohort. 200 patient urine specimens were analysed in this study, derived from 93 healthy individuals
(control), 86 cancer patients (cancer), and urine samples from 21 cancer patients 6 months to 1.5 years after surgery (followup). The cancer-
types of the 86 cancer patients are listed on the right.
Control Cancer Followup Total Oesophagus OGJ Pancreas Gastric Pancreas/Duodenum Duodenum Small bowel
Average age 62 65 68 64 66 62 64 74 60 54 71
Male 72 61 12 145 22 12 16 9 — 1 1
Female 21 25 9 55 5 1 12 6 1 — —
Total 93 86 21 200 27 13 28 15 1 1 1
display a certain degree of heterogeneity, which is easily
overcome by increasing the number of analysed samples.
Using a 20% threshold for peaks commonly found in any
sample, 31.7% of all molecules are present using the IMAC30
(Cu2+) chip-type, 25.2% using CM10, and 23.5% using HP50
surfaces. These low numbers are partially due to the various
disease states and are higher by comparing samples from
healthy control specimens.
Normalising on total ion count and aligning all spec-
tra from individual chip-types resulted in the catalog of
2490 detected peaks, which are fully listed in the database
(Figure 2). The database structure also allows the storage
and retrieval of information relating to the MS environment,
pre- and subfractionation methods, chromatography setups,
studied diseases, and other data. Peak-specific data, such as
identified biomarker, statistical information, and, if known,
identified proteins, are provided. The database covers the
mass range of 1500 to 150000 for SELDI spectra and consists
of averaged and median m/z, intensities and measurement
specific data. All 1172 spectra (raw data files) are available
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Figure 2: Current content of UPdb. UPdb consists of a list of 3874m/z peaks found in human urine in the mass range of 803 to 199000
according to the MS platforms used. The database framework contains data for fractionation methods (separation technique or chip-type,
capillary electrophoresis elution time), mass analyzer used (general technique and specific MS instrumentation used), peak specific data
(average m/z and intensity and frequency above threshold), study-centric information (𝑁, number of specimens tested, literature reference
linking to PubMed, investigated disease, and species), experimental conditions (input volumes, wash conditions for solid phase extraction
methods, andmatrix used), protein links (identified protein name, accession number and link to external databases and internal PADB cross-
references), and sample specific data (whether the sample was in vitro digested or not, from which tissue it originated, and whether it was
further fractionated into subcellular components). Peaks that were classified as biomarkers are indicated in the disease biomarker column,
together with a confidence score (𝑃 value), the regulation (up/down), and fold change in disease as well as substratified frequency %-values
in control and disease samples.
Table 3: Current number of entries in UPdb by source. All current entries in the UPdb database were tallied based on the MS technique
used. The number of detected urinary peaks together with the covered mass range, the medianm/z, the disease areas studied, the number of
identified proteins, and the number of datasets retrieved from the literature are listed.
MS
platform
Number of
peaks
Mass range
m/z
Median
m/z Disease area
Number of
identified
proteins
Number of
external
studies
SELDI 2704 1500–199000 18330
Lupus nephritis, renal allograft nephropathy, cancer,
nephritic syndrome, proteinuria, transplant rejection,
systemic lupus erythematosus, diabetes, and radiocontrast
exposure
27 16
MALDI 45 1220–114000 3212 Cancer 6 3
CE-MS 1125 803–16000 2057
Diabetes, IgA nephropathy, membranous
glomerulonephritis, neonatal ureteropelvic junction
obstruction, renal damage, renal disease, transplant rejection,
and cancer
6 9
CE-MALDI 50 890–6190 2000 Rejection, sepsis, and transplant rejection 0 1
for download in “.xml” format from the PADB website at
http://www.PADB.org/.
Initial literature datamining led to the identification of 29
additional urinary datasets, whichwere incorporated into our
database (Table 3). These sets are based on several MS plat-
forms, ranging from SELDI and MALDI to CE-MS and CE-
MALDI.Themedianmass of each individual MS technology,
based on the identified peaks per technique, shows that both
MALDI and CE-MS favor smaller compounds and peptides,
whereas SELDI has an advantage in the higher mass range,
albeit with a lower resolution of measured peaks. In total,
the database covers a mass range of 800 to 200000m/z or Da
since most peaks using these technologies will have a charge
of one. Currently, of these 3924 peaks, 39 are associated with
identified proteins. This number should continue to rise over
time.Additionally, theUPdbdatabase is part of the Proteomic
Analysis DataBase (PADB) initiative, and a full integration, as
well as development of specific analysis and retrieval tools, is
envisaged.
4. Conclusions
UPdb is accessible and downloadable through the PADB ini-
tiative at http://www. PADB.org/updb/updb.html. This plat-
form should be used as a global resource to share and
exchange primary data derived from SELDI-, MALDI-,
MELDI-, CE-, LC-, and other TOF-MS analyses in urinary
research. We encourage other laboratories to contribute to
UPdb by submitting high quality MS spectra from human
urine samples. We envisage providing full linkage of the
identified m/z species to the large-scale screening resource
(LSSR) database (in preparation), which will list molecules
identified by MS or other large-scale proteomic methods by
6 International Journal of Proteomics
their protein or gene names and will also contain a sub-
stantial database of identified peptide sequences relating to
the proteins listed.
Abbreviations
2-DE: 2 Dimensional electrophoresis
CE: Capillary electrophoresis
ESI: Electrospray ionisation
LC: Liquid chromatography
MALDI: Matrix assisted laser desorption/ionisation
MELDI: Material-enhanced laser desorption/ionization
MS: Mass spectroscopy
SELDI: Surface enhanced laser desorption ionisation
TOF: Time of flight.
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